Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Avalglucosidase Alfa in French Patients With Pompe Disease
NCT05164055Phase 4Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2022
- Primary completion
- Jun 2027
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of avalglucosidase alfa in Pompe disease, sponsored by Sanofi. Started Jul 2022; status: active, not recruiting.
02
Drugs
avalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT05164055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05164055.